Perrigo Company plc or MannKind Corporation: Who Manages SG&A Costs Better?

Who Manages SG&A Costs Better: Perrigo or MannKind?

In the competitive landscape of the pharmaceutical industry, managing Selling, General, and Administrative (SG&A) expenses is crucial for profitability. From 2014 to 2023, Perrigo Company plc consistently outspent MannKind Corporation in SG&A costs, with Perrigo's expenses averaging around 1.1 billion annually, compared to MannKind's 79 million. Despite MannKind's lower absolute costs, Perrigo's strategic investments in SG&A have supported its expansive operations and market reach. Notably, Perrigo's SG&A expenses peaked in 2023, reaching approximately 1.27 billion, a 9% increase from 2022. Meanwhile, MannKind's expenses showed a more modest growth, with a 22% increase over the same period. This data highlights the contrasting strategies of these two companies: Perrigo's aggressive spending to maintain market leadership versus MannKind's leaner approach to cost management. As the industry evolves, these strategies will continue to shape their financial trajectories.